<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Opin Virol</journal-id><journal-id journal-id-type="iso-abbrev">Curr Opin Virol</journal-id><journal-title-group><journal-title>Current Opinion in Virology</journal-title></journal-title-group><issn pub-type="ppub">1879-6257</issn><issn pub-type="epub">1879-6265</issn><publisher><publisher-name>Elsevier B.V.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4195804</article-id><article-id pub-id-type="publisher-id">S1879-6257(14)00137-0</article-id><article-id pub-id-type="doi">10.1016/j.coviro.2014.06.002</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Antiviral drugs specific for coronaviruses in preclinical development</article-title></title-group><contrib-group><contrib contrib-type="author" id="aut0005"><name><surname>Adedeji</surname><given-names>Adeyemi O</given-names></name><email>aoadedeji@ucdavis.edu</email><xref rid="aff0005" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="aut0010"><name><surname>Sarafianos</surname><given-names>Stefan G</given-names></name><email>sarafianoss@missouri.edu</email><email>stefansarafianos@gmail.com</email><xref rid="aff0010" ref-type="aff">2</xref><xref rid="aff0015" ref-type="aff">3</xref><xref rid="aff0020" ref-type="aff">4</xref></contrib><aff id="aff0005"><label>1</label>Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California, Davis, CA 95616, United States</aff><aff id="aff0010"><label>2</label>Christopher Bond Life Sciences Center, University of Missouri, Columbia, MO 65211, United States</aff><aff id="aff0015"><label>3</label>Department of Molecular Microbiology &#x00026; Immunology, University of Missouri School of Medicine, Columbia, MO 65211, United States</aff><aff id="aff0020"><label>4</label>Department of Biochemistry, University of Missouri, Columbia, MO 65211, United States</aff></contrib-group><pub-date pub-type="pmc-release"><day>2</day><month>7</month><year>2014</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>10</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>2</day><month>7</month><year>2014</year></pub-date><volume>8</volume><fpage>45</fpage><lpage>53</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Elsevier B.V. All rights reserved.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Elsevier B.V.</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract abstract-type="author-highlights" id="abs0005"><title>Highlights</title><p><list list-type="simple" id="lis0005"><list-item id="lsti0005"><label>&#x02022;</label><p id="par0005">Coronaviruses are RNA viruses that cause systemic diseases in humans and animals.</p></list-item><list-item id="lsti0010"><label>&#x02022;</label><p id="par0010">There are no approved drugs for the treatment of coronavirus infections.</p></list-item><list-item id="lsti0015"><label>&#x02022;</label><p id="par0015">Several SARS-CoV inhibitors, with known mechanisms of action, have been identified.</p></list-item><list-item id="lsti0020"><label>&#x02022;</label><p id="par0020">These inhibitors stand as promising leads for coronavirus therapeutics.</p></list-item></list></p></abstract><abstract id="abs0010"><p>Coronaviruses are positive stranded RNA viruses that cause respiratory, enteric and central nervous system diseases in many species, including humans. Until recently, the relatively low burden of disease in humans caused by few of these viruses impeded the development of coronavirus specific therapeutics. However, the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV), and more recently, Middle East respiratory syndrome coronavirus (MERS-CoV), has impelled the development of such drugs. This review focuses on some newly identified SARS-CoV inhibitors, with known mechanisms of action and their potential to inhibit the novel MERS-CoV. The clinical development of optimized versions of such compounds could be beneficial for the treatment and control of SARS-CoV, the current MERS-CoV and other future SARS-like epidemics.</p></abstract></article-meta></front><body><p id="par0125">
<boxed-text id="tb0005"><p id="par0130">
<bold>Current Opinion in Virology</bold> 2014, <bold>8</bold>:45&#x02013;53</p><p id="par0135">This review comes from a themed issue on <bold>Antivirals and resistance</bold>
</p><p id="par0140">Edited by <bold>Luis Men&#x000e9;ndez-Arias</bold> and <bold>Douglas D Richman</bold>
</p><p id="par0220">For a complete overview see the <ext-link ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/journal/18796257/8" id="intr1005"><underline>Issue</underline></ext-link> and the <ext-link ext-link-type="doi" xlink:href="10.1016/j.coviro.2014.08.002" id="intr1010"><underline>Editorial</underline></ext-link>
</p><p id="par1240">Available online 2nd July 2014</p><p id="par0115">
<ext-link ext-link-type="doi" xlink:href="10.1016/j.coviro.2014.06.002" id="intr0005"><bold>http://dx.doi.org/10.1016/j.coviro.2014.06.002</bold></ext-link>
</p><p id="par0120">1879-6257/&#x000a9; 2014 Elsevier B.V. All rights reserved.</p></boxed-text>
</p><sec id="sec0005"><title>Introduction</title><p id="par0025">In September 2012, a novel coronavirus (CoV) called Middle East respiratory syndrome CoV (MERS-CoV), was isolated as the causative agent of a severe pneumonia in several patients in the Middle East [<xref rid="bib0005" ref-type="bibr">1</xref>]. Globally, as of May 16, 2014, WHO has been informed of a total of 614 laboratory-confirmed cases of infection with MERS-CoV (including 181 deaths) primarily in the Middle East (Saudi Arabia, Jordan, Qatar, Oman, Kuwait, and the United Arab Emirates), but also in Europe (the UK, France, Italy, Germany, and Greece), North Africa (Tunisia and Egypt), Asia (Malaysia) and the United States of America (<ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/don/2014_05_16_mers/en/" id="intr0010">http://www.who.int/csr/don/2014_05_16_mers/en/</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/coronavirus/mers/" id="intr0015">http://www.cdc.gov/coronavirus/mers/</ext-link>). This CoV is closely related to severe acute respiratory syndrome CoV (SARS-CoV), an epidemic that was short-lived but alarming in 2002&#x02013;2003 that resulted in approximately 8000 cases and 800 deaths.</p><p id="par0030">SARS-CoV and MERS-CoV both belong to the family Coronaviridae, which are enveloped, positive-stranded RNA viruses with approximately 30,000 nucleotides [<xref rid="bib0010" ref-type="bibr">2<sup>&#x02022;&#x02022;</sup></xref>]. CoVs represent the largest RNA viruses. For the well-characterized SARS-CoV, two overlapping open reading frames (ORF1a and ORF1b), encompass approximately two-thirds of the genome. A translational read-through by a &#x02212;1 ribosomal frameshift mechanism allows the translation of the overlapping reading frames into a single polyprotein pp1ab, whereas, translation without the &#x02212;1 ribosomal frameshift mechanism produces pp1a. The polyproteins are later cleaved by two viral proteinases, 3C-like protease (3CLP) and papain-like protease (PLP), to yield non-structural proteins essential for viral replication [<xref rid="bib0015" ref-type="bibr">3</xref>, <xref rid="bib0020" ref-type="bibr">4</xref>]. The remaining one-third of the genome encodes structural proteins of the virus, which include the spike (S), envelope (E), membrane (M) and nucleocapsid (N) proteins [<xref rid="bib0025" ref-type="bibr">5</xref>, <xref rid="bib0030" ref-type="bibr">6</xref>].</p><p id="par0035">On the basis of phylogenic analyses, evolutionary studies have shown that SARS-CoV originated most likely from bats. It has been reported to be transmitted to humans by aerosols through intermediate hosts like palm civets infected by the virus [<xref rid="bib0035" ref-type="bibr">7</xref>, <xref rid="bib0040" ref-type="bibr">8</xref>, <xref rid="bib0045" ref-type="bibr">9</xref>]. Therefore, the zoonosis of CoV is a threat, due to its ability of interspecies transfer into human population. This has been recapitulated with the novel MERS-CoV, as recent studies have suggested that bats and dromedary camels serve as a reservoir for this virus [<xref rid="bib0050" ref-type="bibr">10</xref>, <xref rid="bib0055" ref-type="bibr">11</xref>, <xref rid="bib0060" ref-type="bibr">12</xref>, <xref rid="bib0065" ref-type="bibr">13</xref>, <xref rid="bib0070" ref-type="bibr">14</xref>, <xref rid="bib0075" ref-type="bibr">15</xref>]. MERS-CoV shows SARS-like symptoms following human infections, which include malaise, rigors, fatigues and high fevers, indications similar to influenza, but later progresses to atypical pneumonia in most cases [<xref rid="bib0080" ref-type="bibr">16</xref>].</p><p id="par0040">Although, many antiviral agents have been identified to inhibit SARS <italic>in vitro</italic>, there are presently, no approved antiviral agents or vaccines available to tackle any potential SARS or SARS-like outbreaks, such as MERS. Different parts of the virus, that are deemed viable targets include, 3CLP, PLP, RNA-dependent RNA polymerase (RdRp) and the 5&#x02032;&#x02013;3&#x02032; helicase [<xref rid="bib0085" ref-type="bibr">17</xref>, <xref rid="bib0090" ref-type="bibr">18&#x02022;</xref>, <xref rid="bib0095" ref-type="bibr">19</xref>]. Other possible targets include E protein (Orf4), M protein (Orf6), and N protein (Orf9) [<xref rid="bib0085" ref-type="bibr">17</xref>]. This review focuses on the published antiviral inhibitors of coronaviruses, with SARS-CoV being considered as the primary virus. The inhibitors include replication and entry inhibitors, which can be developed for therapeutic purposes, not just against SARS, but other coronaviruses, including the novel MERS-CoV.</p></sec><sec id="sec0010"><title>Replication inhibitors</title><sec id="sec0015"><title>Protease inhibitors</title><p id="par0045">The first coronavirus proteins that have been studied in detail include viral proteinases, namely the papain-like protease (PLP) or nsp3 and the 3C-like protease (3CLP, nsp5 or Mpro), which cleave the polyprotein into individual polypeptides that are required for replication and transcription [<xref rid="bib0015" ref-type="bibr">3</xref>, <xref rid="bib0020" ref-type="bibr">4</xref>]. Following the translation of the messenger RNA to yield the polyproteins, the 3CLP is first auto-cleaved from the polyproteins to become a mature enzyme. The 3CLP further cleaves all the 11 remaining downstream non-structural proteins. Hence, 3CLP is an essential viral protein for the viral replication cycle, and as a result becomes an attractive target for anti-SARS drug development [<xref rid="bib0100" ref-type="bibr">20</xref>, <xref rid="bib0105" ref-type="bibr">21&#x02022;&#x02022;</xref>, <xref rid="bib0110" ref-type="bibr">22</xref>]. 3CLP inhibitors are among the first SARS-CoV inhibitors that were discovered by screening compound libraries using an assay that utilizes a fluorogenic peptide as the substrate and with structure-based design on the basis of the crystal structures of the product-bound form of 3CLP [<xref rid="bib0115" ref-type="bibr">23</xref>, <xref rid="bib0120" ref-type="bibr">24</xref>, <xref rid="bib0125" ref-type="bibr">25</xref>]. The compounds identified include zinc or mercury conjugates [<xref rid="bib0130" ref-type="bibr">26</xref>, <xref rid="bib0135" ref-type="bibr">27</xref>], C2-symmetric diols [<xref rid="bib0140" ref-type="bibr">28</xref>, <xref rid="bib0145" ref-type="bibr">29</xref>], peptidomimetic &#x003b1;,&#x003b2;-unsaturated esters [<xref rid="bib0150" ref-type="bibr">30</xref>], anilides [<xref rid="bib0155" ref-type="bibr">31</xref>], benzotriazole [<xref rid="bib0160" ref-type="bibr">32</xref>], N-phenyl-2-(2-pyrimidinylthio)acetamide [<xref rid="bib0165" ref-type="bibr">33</xref>], biphenyl sulfone [<xref rid="bib0170" ref-type="bibr">34</xref>], glutamic acid and glutamine peptides possessing a trifluoromethylketone group [<xref rid="bib0175" ref-type="bibr">35</xref>], pyrimidinone [<xref rid="bib0180" ref-type="bibr">36</xref>], and pyrazole analogs that can also inhibit 3Cpro of picornaviruses CV-B3 (coxsackievirus), EV-71 (enterovirus) and RV-14 (rhinovirus) (coronavirus and picornavirus dual inhibitors) [<xref rid="bib0120" ref-type="bibr">24</xref>, <xref rid="bib0125" ref-type="bibr">25</xref>]. The names and chemical structures of some of the published 3C-protease inhibitors are shown in <xref rid="fig0005" ref-type="fig">Figure 1</xref>
.<fig id="fig0005"><label>Figure 1</label><caption><p>Names and chemical structures of examples of SARS-CoV 3CLP and PLP protease inhibitors.</p></caption><graphic xlink:href="gr1"/></fig></p><p id="par0050">The papain like protease (PLP) is also an essential component of the SARS-CoV replication machinery. PLP is the nsp3 protein which is part of the synthesized ORF1a polyprotein during replication. nsp3 cleaves protease recognition sites between nsp1/2, nsp2/3 and nsp3/4 [<xref rid="bib0185" ref-type="bibr">37</xref>]. In addition to its protease activity, nsp3 has been shown to have deubiquitination, and interferon antagonist activities <italic>in vitro</italic> [<xref rid="bib0190" ref-type="bibr">38</xref>]. Since its homologues are found in all coronaviruses, it has also been proposed to be a good target for drug discovery for both SARS-CoV and other human coronaviruses.</p><p id="par0055">Recently, Frieman <italic>et al.</italic> [<xref rid="bib0195" ref-type="bibr">39</xref>] developed a yeast-based assay to screen for small molecules that block SARS-CoV replication on the basis of their inhibition of nsp3 or PLP. The basis for the screen was that stimulated expression of nsp3 in <italic>Saccharomyces cerevisiae</italic> causes a pronounced slow growth phenotype. Using this principle, they screened a small molecule library for compounds that specifically prevented the nsp3-induced slow growth phenotype. These compounds were then validated in cell culture models for efficacy against SARS-CoV replication, as well as the known enzymatic functions of nsp3. The authors found five compounds that reversed the slow growth phenotype in yeast. One of the compounds, NSC158362 (<xref rid="fig0005" ref-type="fig">Figure 1</xref>g), considerably blocked SARS-CoV replication <italic>in vitro</italic> with an EC<sub>50</sub>
&#x000a0;&#x0003c;&#x000a0;1&#x000a0;&#x003bc;M. This effect was specific for SARS-CoV replication because no effect on influenza virus replication was observed with up to 50&#x000a0;&#x003bc;M of the inhibitory compound. Another compound, NSC158011, was shown to inhibit nsp3-dependent protease activity in a cell culture assay, but could not prevent virus replication. NSC158362, could not inhibit the protease, deubiquitinase or anti-IFN activities of nsp3, therefore suggesting that the compound may be inhibiting a yet unknown novel activity of nsp3 required for viral replication or may be inhibiting some cellular factors that regulate nsp3 function in infected cells.</p></sec><sec id="sec0020"><title>Helicase inhibitors</title><p id="par0060">Helicases are proteins that catalyze the separation of duplex oligonucleotides into single strands in an ATP-dependent reaction. On the basis of this activity, helicases can be divided into two types: those that unwind duplexes in a 3&#x02032;&#x02192;5&#x02032; direction, and those that unwind in a 5&#x02032;&#x02192;3&#x02032; direction. Helicases require a molecular mechanism for transducing the chemical energy generated by the ATPase activity into an oligonucleotide strand separation and displacement activity [<xref rid="bib0200" ref-type="bibr">40</xref>]. The functions of helicase in positive-sense RNA viruses include nucleic acid separations [<xref rid="bib0205" ref-type="bibr">41<sup>&#x02022;&#x02022;</sup></xref>], the melting of highly stable secondary structures within the genomic RNA in order to increase translational efficiency of the polyprotein [<xref rid="bib0210" ref-type="bibr">42</xref>]. Considering all these helicase functions, viral helicases stand as a strong antiviral target.</p><p id="par0065">The helicase of SARS-CoV is called nsp13. A few potential inhibitors of nsp13 have been identified [<xref rid="bib0095" ref-type="bibr">19</xref>, <xref rid="bib0215" ref-type="bibr">43</xref>, <xref rid="bib0220" ref-type="bibr">44</xref>, <xref rid="bib0225" ref-type="bibr">45</xref>, <xref rid="bib0230" ref-type="bibr">46</xref>]. Some of these inhibitors inhibit nsp13 by interfering with its unwinding and ATPase activities. They include the bananins and the 5-hydroxychromone derivatives [<xref rid="bib0215" ref-type="bibr">43</xref>, <xref rid="bib0225" ref-type="bibr">45</xref>]. The bananins are a class of antiviral compounds with an exclusive structural signature that incorporates a trioxa-adamantane moiety covalently bound to a pyridoxal derivative [<xref rid="bib0225" ref-type="bibr">45</xref>]. Six members of this class of compounds were synthesized by Tanner <italic>et al</italic>. [<xref rid="bib0225" ref-type="bibr">45</xref>]. The compounds are bananin, iodobananin, vanillinbananin, ansabananin, eubananin, and adeninobananin. Of the six compounds, bananin, iodobananin, vanillinbananin, and eubananin effectively inhibited the helicase activity of nsp13 by inhibiting the ATPase activity of the helicase with IC<sub>50</sub> values in the range 0.5&#x02013;3&#x000a0;&#x003bc;M. Bananin was also shown to exhibit antiviral activity against SARS-CoV in a cell culture assay, with an EC50 of less than 10&#x000a0;&#x003bc;M [<xref rid="bib0225" ref-type="bibr">45</xref>]. The structure of vanillinbananin is shown in <xref rid="fig0010" ref-type="fig">Figure 2</xref>a. For the 5-hydroxychromone derivatives, 5-hydroxychromone was used as a scaffold on which two arylmethyloxy substituents were installed. The resulting derivatives include 5-hydroxy-6-(3-chlorobenzyloxy)-chromone with chloro-benzyloxy or iodo-benzyloxy substituents [<xref rid="bib0215" ref-type="bibr">43</xref>] (<xref rid="fig0010" ref-type="fig">Figure 2</xref>b). These compounds, similar to the bananins, also inhibited the unwinding activities of SARS-CoV nsp13 by inhibiting the ATPase activity of the helicase at comparable EC<sub>50</sub>s of &#x0223c;10&#x000a0;&#x003bc;M [<xref rid="bib0215" ref-type="bibr">43</xref>]. Although these compounds portend to be a promising therapy, the potential ability of these compounds to inhibit the ATPase activity of cellular ATPases or kinases may affect cellular activities, thereby creating a risk of cytotoxicity. A study reported that an aryl diketoacid compound (<xref rid="fig0010" ref-type="fig">Figure 2</xref>c) selectively inhibited the duplex DNA unwinding activity of SARS-CoV nsp13 without significantly inhibiting its ATPase activity [<xref rid="bib0220" ref-type="bibr">44</xref>]. However, the effects of this compound on nsp13's unwinding activity of double-stranded RNA (dsRNA) and the replication of SARS-CoV were not determined [<xref rid="bib0220" ref-type="bibr">44</xref>].<fig id="fig0010"><label>Figure 2</label><caption><p>Names and chemical structures of examples of SARS-CoV helicase inhibitors.</p></caption><graphic xlink:href="gr2"/></fig></p><p id="par0070">A recent report revealed an inhibitor of nsp13 that inhibited the unwinding, but not the ATPase enzymatic and nucleic acid binding activities of nsp13 [<xref rid="bib0095" ref-type="bibr">19</xref>]. Using biochemical analyses, the authors demonstrated that this compound, SSYA10-001 (<xref rid="fig0010" ref-type="fig">Figure 2</xref>d), is a noncompetitive inhibitor of nsp13 with respect to its major substrates, namely, nucleic acids and ATP. Since this compound did not inhibit nsp13's binding and hydrolysis of nucleic acids and ATP, coupled with the fact that it did not bind the nucleic acid substrate, the authors suggested that, SSYA10-001 may be inhibiting nsp13 unwinding activity by interfering with its conformational changes during the course of the reaction or translocation on the nucleic acid [<xref rid="bib0095" ref-type="bibr">19</xref>]. Moreover, SSYA10-001 was also shown to be an efficient inhibitor of viral replication in a SARS-CoV replicon and live viral assays. More recently, SSYA10-001 was shown to exhibit a broad-spectrum activity against other coronaviruses, including MERS-CoV and mouse hepatitis virus (MHV) [<xref rid="bib0235" ref-type="bibr">47</xref>].</p></sec><sec id="sec0025"><title>Entry inhibitors</title><p id="par0075">Viral entry is an essential step of the virus replication cycle that can be targeted for therapy [<xref rid="bib0240" ref-type="bibr">48</xref>]. Entry inhibitors of several viruses have been identified. Examples include: RFI 641 and VP-14637, which are small molecules that inhibit the entry of respiratory syncytial virus by binding at a hydrophobic pocket of the fusion (F) glycoprotein [<xref rid="bib0245" ref-type="bibr">49</xref>, <xref rid="bib0250" ref-type="bibr">50</xref>]; some inhibitors have been reported to block HIV entry by using different strategies. Maraviroc is an entry inhibitor of HIV that targets CCR5, a host protein used as a coreceptor during HIV entry [<xref rid="bib0255" ref-type="bibr">51</xref>, <xref rid="bib0260" ref-type="bibr">52</xref>, <xref rid="bib0265" ref-type="bibr">53</xref>]. Enfuvirtide and SC29EK are peptides that can also block viral entry by binding to the viral transmembrane protein gp41 and blocking the final stage of fusion with the target cell [<xref rid="bib0270" ref-type="bibr">54</xref>, <xref rid="bib0275" ref-type="bibr">55</xref>, <xref rid="bib0280" ref-type="bibr">56</xref>, <xref rid="bib0285" ref-type="bibr">57</xref>, <xref rid="bib0290" ref-type="bibr">58</xref>, <xref rid="bib0295" ref-type="bibr">59</xref>]. A few monoclonal antibodies are currently in clinical trials, and they include KD-247 and PRO140. They prevent HIV entry by binding either the viral surface glycoprotein gp120 [<xref rid="bib0300" ref-type="bibr">60</xref>, <xref rid="bib0305" ref-type="bibr">61</xref>] or the CCR5 coreceptor [<xref rid="bib0310" ref-type="bibr">62</xref>, <xref rid="bib0315" ref-type="bibr">63</xref>].</p><p id="par0080">The surface glycoprotein of SARS-CoV, SARS-S, has two constituents: S1, which comprises the receptor binding domain (RBD), and S2, which comprises the fusion peptide. SARS-CoV gains entry into permissive cells through interactions of the SARS-S RBD with the cell surface receptor, angiotensin converting enzyme 2 (ACE2) (<xref rid="fig0015" ref-type="fig">Figure 3</xref>
) [<xref rid="bib0100" ref-type="bibr">20</xref>, <xref rid="bib0320" ref-type="bibr">64</xref>]. Following these interactions, endocytosis occurs. When the endosomes are within the region of low pH in the cell, SARS-S is cleaved by a cellular protease called cathepsin L (<xref rid="fig0020" ref-type="fig">Figure 4</xref>
), leading to the exposure of the S2 domain of the spike protein for membrane fusion [<xref rid="bib0325" ref-type="bibr">65</xref>, <xref rid="bib0330" ref-type="bibr">66</xref>, <xref rid="bib0335" ref-type="bibr">67&#x02022;&#x02022;</xref>, <xref rid="bib0340" ref-type="bibr">68</xref>, <xref rid="bib0345" ref-type="bibr">69&#x02022;&#x02022;</xref>, <xref rid="bib0350" ref-type="bibr">70</xref>]. Some reports have also suggested the possibility of the fusion of SARS-S-expressing cells with ACE2 receptor-expressing cells in a pH-independent environment at the cell surface [<xref rid="bib0355" ref-type="bibr">71</xref>, <xref rid="bib0360" ref-type="bibr">72</xref>].<fig id="fig0015"><label>Figure 3</label><caption><p>Model for the different stages of SARS-CoV entry that are potential antiviral targets.</p></caption><graphic xlink:href="gr3"/></fig><fig id="fig0020"><label>Figure 4</label><caption><p>Examples of SARS-CoV entry inhibitors.</p></caption><graphic xlink:href="gr4"/></fig></p><p id="par0085">The possible targets for SARS viral entry, thus, include cathepsin L, ACE2&#x02013;SARS-S1 interaction and S2-cell membrane fusion (<xref rid="fig0015" ref-type="fig">Figure 3</xref>). A number of studies have identified some inhibitors that interfere with these targets. Dipeptide epoxyketones, calpain inhibitor III, oxocarbazate, MDL28170 and SSAA09E1 are all cathepsin L inhibitors (<xref rid="fig0020" ref-type="fig">Figure 4</xref>) [<xref rid="bib0335" ref-type="bibr">67&#x02022;&#x02022;</xref>, <xref rid="bib0365" ref-type="bibr">73</xref>, <xref rid="bib0370" ref-type="bibr">74</xref>, <xref rid="bib0375" ref-type="bibr">75</xref>, <xref rid="bib0380" ref-type="bibr">76&#x02022;&#x02022;</xref>, <xref rid="bib0385" ref-type="bibr">77&#x02022;&#x02022;</xref>]. Although the first four compounds are peptidomimetic in nature (<xref rid="fig0020" ref-type="fig">Figure 4</xref>a&#x02013;c), SSAA09E1 (<xref rid="fig0020" ref-type="fig">Figure 4</xref>d) is a small molecule cathepsin L inhibitor that is likely to have improved bioavailability over others. These compounds have been shown to inhibit SARS viral entry by hindering the ability of cathepsin L to cleave S1 from S2, thereby preventing the fusion of the viral envelope with the host cell membrane, following endocytosis. Other SARS viral entry inhibitors include SSAA09E2 (<xref rid="fig0020" ref-type="fig">Figure 4</xref>e), SSAA09E3 (<xref rid="fig0020" ref-type="fig">Figure 4</xref>f), and NAAE (N-(2-aminoethyl)-l-aziridine-ethanamine), all of which are small molecule compounds. SSAA09E3 [<xref rid="bib0385" ref-type="bibr">77<sup>&#x02022;&#x02022;</sup></xref>] prevents fusion of the viral membrane with the host cellular membrane (<xref rid="fig0015" ref-type="fig">Figure 3</xref>, <xref rid="fig0020" ref-type="fig">Figure 4</xref>). SSAA09E2 [<xref rid="bib0385" ref-type="bibr">77<sup>&#x02022;&#x02022;</sup></xref>] and NAAE [<xref rid="bib0390" ref-type="bibr">78</xref>] act by blocking early interactions of SARS-S with the receptor for SARS-CoV, angiotensin converting enzyme 2 (ACE2) (<xref rid="fig0015" ref-type="fig">Figure 3</xref>). NAAE is a unique small molecule entry inhibitor in that, it inhibits both ACE2 catalytic activity and S-protein-induced cell-cell fusion [<xref rid="bib0390" ref-type="bibr">78</xref>]. Although dual inhibitory effects on ACE2 catalytic activity and SARS-CoV binding is not expected, because the catalytic site of ACE2 is distinct from the S-protein-binding domain [<xref rid="bib0355" ref-type="bibr">71</xref>, <xref rid="bib0395" ref-type="bibr">79&#x02022;&#x02022;</xref>], NAAE did show antiviral activity. Overexpression of ACE has been shown to cause hypertension, which is counterbalanced by ACE2 (through vasodilation) [<xref rid="bib0400" ref-type="bibr">80</xref>]. Hence, inhibition of ACE2 by NAAE stands as a potential risk for hypertension.</p></sec></sec><sec id="sec0030"><title>Making a case for clinical development of coronavirus inhibitors</title><p id="par0090">Currently, there are no approved drugs for the treatment of SARS-CoV infection. During the initial outbreak of SARS, a number of medications that included ribavirin with and without corticosteroids [<xref rid="bib0405" ref-type="bibr">81</xref>, <xref rid="bib0410" ref-type="bibr">82</xref>, <xref rid="bib0415" ref-type="bibr">83</xref>], interferon (alfacon-1) with corticosteroids [<xref rid="bib0420" ref-type="bibr">84</xref>], and ribavirin with protease inhibitors [<xref rid="bib0425" ref-type="bibr">85</xref>] had some encouraging outcomes, but a definitive treatment regimen was not clearly established. More recently, a combination of IFN-&#x003b1;2b and ribavirin were shown to have some <italic>in vitro</italic> synergistic activities against MERS-CoV, albeit at higher concentrations [<xref rid="bib0430" ref-type="bibr">86</xref>]. These drugs have known pharmacological properties and are, therefore, widely available, as some of them are used for the treatment of some viral infections, such as hepatitis C virus, albeit with some adverse side effects including hemolytic anemia, elevated transaminase levels and bradycardia [<xref rid="bib0415" ref-type="bibr">83</xref>], depression, suicide, relapse of drug abuse/overdose, bacterial infections and many others (Interferon and ribavirin treatment side effects, <ext-link ext-link-type="uri" xlink:href="http://www.hepatitis.va.gov/provider/reviews/treatment-side-effects.asp" id="intr0020">http://www.hepatitis.va.gov/provider/reviews/treatment-side-effects.asp#S1X</ext-link>). Hence, with the new outbreak of MERS-CoV infection, optimization and development of some of the aforementioned lead compounds or other inhibitors with known or new mechanisms of action becomes important for therapeutic purposes, as there are no reports of any compound in clinical trials.</p></sec><sec id="sec0035"><title>References and recommended reading</title><p id="par0095">Papers of particular interest, published within the period of review, have been highlighted as:<list list-type="simple" id="lis0010"><list-item id="lsti0025"><p id="par0100">&#x02022; of special interest</p></list-item><list-item id="lsti0030"><p id="par0105">&#x02022;&#x02022; of outstanding interest</p></list-item></list>
</p></sec></body><back><ref-list id="bibl0005"><title>References</title><ref id="bib0005"><label>1</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name><surname>Zaki</surname><given-names>A.M.</given-names></name><name><surname>van Boheemen</surname><given-names>S.</given-names></name><name><surname>Bestebroer</surname><given-names>T.M.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name><name><surname>Fouchier</surname><given-names>R.A.</given-names></name></person-group><article-title>Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia</article-title><source>N Engl J Med</source><volume>367</volume><year>2012</year><fpage>1814</fpage><lpage>1820</lpage><pub-id pub-id-type="pmid">23075143</pub-id></element-citation></ref><ref id="bib0010"><label>2&#x02022;&#x02022;</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name><surname>Rota</surname><given-names>P.A.</given-names></name><name><surname>Oberste</surname><given-names>M.S.</given-names></name><name><surname>Monroe</surname><given-names>S.S.</given-names></name><name><surname>Nix</surname><given-names>W.A.</given-names></name><name><surname>Campagnoli</surname><given-names>R.</given-names></name><name><surname>Icenogle</surname><given-names>J.P.</given-names></name><name><surname>Penaranda</surname><given-names>S.</given-names></name><name><surname>Bankamp</surname><given-names>B.</given-names></name><name><surname>Maher</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>M.H.</given-names></name></person-group><article-title>Characterization of a novel coronavirus associated with severe acute respiratory syndrome</article-title><source>Science</source><volume>300</volume><year>2003</year><fpage>1394</fpage><lpage>1399</lpage><pub-id pub-id-type="pmid">12730500</pub-id></element-citation><note><p>This is the first report for the complete sequence of SARS-CoV complete genome with phylogenetic analyses and sequence comparisons indicating its novelty.</p></note></ref><ref id="bib0015"><label>3</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name><surname>Thiel</surname><given-names>V.</given-names></name><name><surname>Herold</surname><given-names>J.</given-names></name><name><surname>Schelle</surname><given-names>B.</given-names></name><name><surname>Siddell</surname><given-names>S.G.</given-names></name></person-group><article-title>Viral replicase gene products suffice for coronavirus discontinuous transcription</article-title><source>J Virol</source><volume>75</volume><year>2001</year><fpage>6676</fpage><lpage>6681</lpage><pub-id pub-id-type="pmid">11413334</pub-id></element-citation></ref><ref id="bib0020"><label>4</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name><surname>Thiel</surname><given-names>V.</given-names></name><name><surname>Ivanov</surname><given-names>K.A.</given-names></name><name><surname>Putics</surname><given-names>A.</given-names></name><name><surname>Hertzig</surname><given-names>T.</given-names></name><name><surname>Schelle</surname><given-names>B.</given-names></name><name><surname>Bayer</surname><given-names>S.</given-names></name><name><surname>Weissbrich</surname><given-names>B.</given-names></name><name><surname>Snijder</surname><given-names>E.J.</given-names></name><name><surname>Rabenau</surname><given-names>H.</given-names></name><name><surname>Doerr</surname><given-names>H.W.</given-names></name></person-group><article-title>Mechanisms and enzymes involved in SARS coronavirus genome expression</article-title><source>J Gen Virol</source><volume>84</volume><year>2003</year><fpage>2305</fpage><lpage>2315</lpage><pub-id pub-id-type="pmid">12917450</pub-id></element-citation></ref><ref id="bib0025"><label>5</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name><surname>Narayanan</surname><given-names>K.</given-names></name><name><surname>Maeda</surname><given-names>A.</given-names></name><name><surname>Maeda</surname><given-names>J.</given-names></name><name><surname>Makino</surname><given-names>S.</given-names></name></person-group><article-title>Characterization of the coronavirus M protein and nucleocapsid interaction in infected cells</article-title><source>J Virol</source><volume>74</volume><year>2000</year><fpage>8127</fpage><lpage>8134</lpage><pub-id pub-id-type="pmid">10933723</pub-id></element-citation></ref><ref id="bib0030"><label>6</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name><surname>Opstelten</surname><given-names>D.J.</given-names></name><name><surname>Raamsman</surname><given-names>M.J.</given-names></name><name><surname>Wolfs</surname><given-names>K.</given-names></name><name><surname>Horzinek</surname><given-names>M.C.</given-names></name><name><surname>Rottier</surname><given-names>P.J.</given-names></name></person-group><article-title>Envelope glycoprotein interactions in coronavirus assembly</article-title><source>J Cell Biol</source><volume>131</volume><year>1995</year><fpage>339</fpage><lpage>349</lpage><pub-id pub-id-type="pmid">7593163</pub-id></element-citation></ref><ref id="bib0035"><label>7</label><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name><surname>Hon</surname><given-names>C.C.</given-names></name><name><surname>Lam</surname><given-names>T.Y.</given-names></name><name><surname>Shi</surname><given-names>Z.L.</given-names></name><name><surname>Drummond</surname><given-names>A.J.</given-names></name><name><surname>Yip</surname><given-names>C.W.</given-names></name><name><surname>Zeng</surname><given-names>F.</given-names></name><name><surname>Lam</surname><given-names>P.Y.</given-names></name><name><surname>Leung</surname><given-names>F.C.</given-names></name></person-group><article-title>Evidence of the recombinant origin of a bat severe acute respiratory syndrome (SARS)-like coronavirus and its implications on the direct ancestor of SARS coronavirus</article-title><source>J Virol</source><volume>82</volume><year>2008</year><fpage>1819</fpage><lpage>1826</lpage><pub-id pub-id-type="pmid">18057240</pub-id></element-citation></ref><ref id="bib0040"><label>8</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Yu</surname><given-names>M.</given-names></name><name><surname>Ren</surname><given-names>W.</given-names></name><name><surname>Smith</surname><given-names>C.</given-names></name><name><surname>Epstein</surname><given-names>J.H.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Crameri</surname><given-names>G.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name></person-group><article-title>Bats are natural reservoirs of SARS-like coronaviruses</article-title><source>Science</source><volume>310</volume><year>2005</year><fpage>676</fpage><lpage>679</lpage><pub-id pub-id-type="pmid">16195424</pub-id></element-citation></ref><ref id="bib0045"><label>9</label><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.F.</given-names></name><name><surname>Eaton</surname><given-names>B.T.</given-names></name></person-group><article-title>Bats, civets and the emergence of SARS</article-title><source>Curr Top Microbiol Immunol</source><volume>315</volume><year>2007</year><fpage>325</fpage><lpage>344</lpage><pub-id pub-id-type="pmid">17848070</pub-id></element-citation></ref><ref id="bib0050"><label>10</label><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name><surname>Haagmans</surname><given-names>B.L.</given-names></name><name><surname>Al Dhahiry</surname><given-names>S.H.</given-names></name><name><surname>Reusken</surname><given-names>C.B.</given-names></name><name><surname>Raj</surname><given-names>V.S.</given-names></name><name><surname>Galiano</surname><given-names>M.</given-names></name><name><surname>Myers</surname><given-names>R.</given-names></name><name><surname>Godeke</surname><given-names>G.J.</given-names></name><name><surname>Jonges</surname><given-names>M.</given-names></name><name><surname>Farag</surname><given-names>E.</given-names></name><name><surname>Diab</surname><given-names>A.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation</article-title><source>Lancet Infect Dis</source><volume>14</volume><year>2013</year><fpage>140</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">24355866</pub-id></element-citation></ref><ref id="bib0055"><label>11</label><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name><surname>Abdel-Moneim</surname><given-names>A.S.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus (MERS-CoV): evidence and speculations</article-title><source>Arch Virol</source><year>2014</year></element-citation></ref><ref id="bib0060"><label>12</label><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name><surname>Annan</surname><given-names>A.</given-names></name><name><surname>Baldwin</surname><given-names>H.J.</given-names></name><name><surname>Corman</surname><given-names>V.M.</given-names></name><name><surname>Klose</surname><given-names>S.M.</given-names></name><name><surname>Owusu</surname><given-names>M.</given-names></name><name><surname>Nkrumah</surname><given-names>E.E.</given-names></name><name><surname>Badu</surname><given-names>E.K.</given-names></name><name><surname>Anti</surname><given-names>P.</given-names></name><name><surname>Agbenyega</surname><given-names>O.</given-names></name><name><surname>Meyer</surname><given-names>B.</given-names></name></person-group><article-title>Human betacoronavirus 2c EMC/2012-related viruses in bats, Ghana and Europe</article-title><source>Emerg Infect Dis</source><volume>19</volume><year>2013</year><fpage>456</fpage><lpage>459</lpage><pub-id pub-id-type="pmid">23622767</pub-id></element-citation></ref><ref id="bib0065"><label>13</label><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name><surname>Anthony</surname><given-names>S.J.</given-names></name><name><surname>Ojeda-Flores</surname><given-names>R.</given-names></name><name><surname>Rico-Chavez</surname><given-names>O.</given-names></name><name><surname>Navarrete-Macias</surname><given-names>I.</given-names></name><name><surname>Zambrana-Torrelio</surname><given-names>C.M.</given-names></name><name><surname>Rostal</surname><given-names>M.K.</given-names></name><name><surname>Epstein</surname><given-names>J.H.</given-names></name><name><surname>Tipps</surname><given-names>T.</given-names></name><name><surname>Liang</surname><given-names>E.</given-names></name><name><surname>Sanchez-Leon</surname><given-names>M.</given-names></name></person-group><article-title>Coronaviruses in bats from Mexico</article-title><source>J Gen Virol</source><volume>94</volume><year>2013</year><fpage>1028</fpage><lpage>1038</lpage><pub-id pub-id-type="pmid">23364191</pub-id></element-citation></ref><ref id="bib0070"><label>14</label><element-citation publication-type="journal" id="sbref0070"><person-group person-group-type="author"><name><surname>van Boheemen</surname><given-names>S.</given-names></name><name><surname>de Graaf</surname><given-names>M.</given-names></name><name><surname>Lauber</surname><given-names>C.</given-names></name><name><surname>Bestebroer</surname><given-names>T.M.</given-names></name><name><surname>Raj</surname><given-names>V.S.</given-names></name><name><surname>Zaki</surname><given-names>A.M.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name><name><surname>Haagmans</surname><given-names>B.L.</given-names></name><name><surname>Gorbalenya</surname><given-names>A.E.</given-names></name><name><surname>Snijder</surname><given-names>E.J.</given-names></name></person-group><article-title>Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans</article-title><source>MBio</source><year>2012</year><fpage>3</fpage></element-citation></ref><ref id="bib0075"><label>15</label><element-citation publication-type="journal" id="sbref0075"><person-group person-group-type="author"><name><surname>Ithete</surname><given-names>N.L.</given-names></name><name><surname>Stoffberg</surname><given-names>S.</given-names></name><name><surname>Corman</surname><given-names>V.M.</given-names></name><name><surname>Cottontail</surname><given-names>V.M.</given-names></name><name><surname>Richards</surname><given-names>L.R.</given-names></name><name><surname>Schoeman</surname><given-names>M.C.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name><name><surname>Drexler</surname><given-names>J.F.</given-names></name><name><surname>Preiser</surname><given-names>W.</given-names></name></person-group><article-title>Close relative of human Middle East respiratory syndrome coronavirus in bat, South Africa</article-title><source>Emerg Infect Dis</source><volume>19</volume><year>2013</year><fpage>1697</fpage><lpage>1699</lpage><pub-id pub-id-type="pmid">24050621</pub-id></element-citation></ref><ref id="bib0080"><label>16</label><element-citation publication-type="journal" id="sbref0080"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>J.S.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name><name><surname>Stohr</surname><given-names>K.</given-names></name></person-group><article-title>The severe acute respiratory syndrome</article-title><source>N Engl J Med</source><volume>349</volume><year>2003</year><fpage>2431</fpage><lpage>2441</lpage><pub-id pub-id-type="pmid">14681510</pub-id></element-citation></ref><ref id="bib0085"><label>17</label><element-citation publication-type="journal" id="sbref0085"><person-group person-group-type="author"><name><surname>Barnard</surname><given-names>D.L.</given-names></name><name><surname>Kumaki</surname><given-names>Y.</given-names></name></person-group><article-title>Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy</article-title><source>Future Virol</source><volume>6</volume><year>2011</year><fpage>615</fpage><lpage>631</lpage><pub-id pub-id-type="pmid">21765859</pub-id></element-citation></ref><ref id="bib0090"><label>18&#x02022;</label><element-citation publication-type="journal" id="sbref0090"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>P.H.</given-names></name></person-group><article-title>Characterization and inhibition of SARS-coronavirus main protease</article-title><source>Curr Top Med Chem</source><volume>6</volume><year>2006</year><fpage>361</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">16611148</pub-id></element-citation><note><p>This review focuses on the detailed characterization of SARS-coronavirus main protease in relation to the inhibitors.</p></note></ref><ref id="bib0095"><label>19</label><element-citation publication-type="journal" id="sbref0095"><person-group person-group-type="author"><name><surname>Adedeji</surname><given-names>A.O.</given-names></name><name><surname>Singh</surname><given-names>K.</given-names></name><name><surname>Calcaterra</surname><given-names>N.E.</given-names></name><name><surname>DeDiego</surname><given-names>M.L.</given-names></name><name><surname>Enjuanes</surname><given-names>L.</given-names></name><name><surname>Weiss</surname><given-names>S.</given-names></name><name><surname>Sarafianos</surname><given-names>S.G.</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase</article-title><source>Antimicrob Agents Chemother</source><volume>56</volume><year>2012</year><fpage>4718</fpage><lpage>4728</lpage><pub-id pub-id-type="pmid">22733076</pub-id></element-citation></ref><ref id="bib0100"><label>20</label><element-citation publication-type="journal" id="sbref0100"><person-group person-group-type="author"><name><surname>Anand</surname><given-names>K.</given-names></name><name><surname>Ziebuhr</surname><given-names>J.</given-names></name><name><surname>Wadhwani</surname><given-names>P.</given-names></name><name><surname>Mesters</surname><given-names>J.R.</given-names></name><name><surname>Hilgenfeld</surname><given-names>R.</given-names></name></person-group><article-title>Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs</article-title><source>Science</source><volume>300</volume><year>2003</year><fpage>1763</fpage><lpage>1767</lpage><pub-id pub-id-type="pmid">12746549</pub-id></element-citation></ref><ref id="bib0105"><label>21&#x02022;&#x02022;</label><element-citation publication-type="journal" id="sbref0105"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Ding</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Lou</surname><given-names>Z.</given-names></name><name><surname>Zhou</surname><given-names>Z.</given-names></name><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Mo</surname><given-names>L.</given-names></name><name><surname>Ye</surname><given-names>S.</given-names></name><name><surname>Pang</surname><given-names>H.</given-names></name></person-group><article-title>The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor</article-title><source>Proc Natl Acad Sci U S A</source><volume>100</volume><year>2003</year><fpage>13190</fpage><lpage>13195</lpage><pub-id pub-id-type="pmid">14585926</pub-id></element-citation><note><p>This is the first report on the crystal structures of severe acute respiratory syndrome virus main protease at different pH and its complex with a specific inhibitor.</p></note></ref><ref id="bib0110"><label>22</label><element-citation publication-type="journal" id="sbref0110"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Xie</surname><given-names>W.</given-names></name><name><surname>Xue</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>K.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Liang</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>Q.</given-names></name><name><surname>Zhou</surname><given-names>Z.</given-names></name><name><surname>Pei</surname><given-names>D.</given-names></name><name><surname>Ziebuhr</surname><given-names>J.</given-names></name></person-group><article-title>Design of wide-spectrum inhibitors targeting coronavirus main proteases</article-title><source>PLoS Biol</source><volume>3</volume><year>2005</year><fpage>e324</fpage><pub-id pub-id-type="pmid">16128623</pub-id></element-citation></ref><ref id="bib0115"><label>23</label><element-citation publication-type="journal" id="sbref0115"><person-group person-group-type="author"><name><surname>Ramajayam</surname><given-names>R.</given-names></name><name><surname>Tan</surname><given-names>K.P.</given-names></name><name><surname>Liang</surname><given-names>P.H.</given-names></name></person-group><article-title>Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery</article-title><source>Biochem Soc Trans</source><volume>39</volume><year>2011</year><fpage>1371</fpage><lpage>1375</lpage><pub-id pub-id-type="pmid">21936817</pub-id></element-citation></ref><ref id="bib0120"><label>24</label><element-citation publication-type="journal" id="sbref0120"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>C.J.</given-names></name><name><surname>Liu</surname><given-names>H.G.</given-names></name><name><surname>Lo</surname><given-names>Y.K.</given-names></name><name><surname>Seong</surname><given-names>C.M.</given-names></name><name><surname>Lee</surname><given-names>K.I.</given-names></name><name><surname>Jung</surname><given-names>Y.S.</given-names></name><name><surname>Liang</surname><given-names>P.H.</given-names></name></person-group><article-title>Individual and common inhibitors of coronavirus and picornavirus main proteases</article-title><source>FEBS Lett</source><volume>583</volume><year>2009</year><fpage>549</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">19166843</pub-id></element-citation></ref><ref id="bib0125"><label>25</label><element-citation publication-type="journal" id="sbref0125"><person-group person-group-type="author"><name><surname>Ramajayam</surname><given-names>R.</given-names></name><name><surname>Tan</surname><given-names>K.P.</given-names></name><name><surname>Liu</surname><given-names>H.G.</given-names></name><name><surname>Liang</surname><given-names>P.H.</given-names></name></person-group><article-title>Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors</article-title><source>Bioorg Med Chem</source><volume>18</volume><year>2010</year><fpage>7849</fpage><lpage>7854</lpage><pub-id pub-id-type="pmid">20947359</pub-id></element-citation></ref><ref id="bib0130"><label>26</label><element-citation publication-type="journal" id="sbref0130"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>J.T.</given-names></name><name><surname>Kuo</surname><given-names>C.J.</given-names></name><name><surname>Hsieh</surname><given-names>H.P.</given-names></name><name><surname>Wang</surname><given-names>Y.C.</given-names></name><name><surname>Huang</surname><given-names>K.K.</given-names></name><name><surname>Lin</surname><given-names>C.P.</given-names></name><name><surname>Huang</surname><given-names>P.F.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Liang</surname><given-names>P.H.</given-names></name></person-group><article-title>Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV</article-title><source>FEBS Lett</source><volume>574</volume><year>2004</year><fpage>116</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">15358550</pub-id></element-citation></ref><ref id="bib0135"><label>27</label><element-citation publication-type="journal" id="sbref0135"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>C.C.</given-names></name><name><surname>Kuo</surname><given-names>C.J.</given-names></name><name><surname>Hsu</surname><given-names>M.F.</given-names></name><name><surname>Liang</surname><given-names>P.H.</given-names></name><name><surname>Fang</surname><given-names>J.M.</given-names></name><name><surname>Shie</surname><given-names>J.J.</given-names></name><name><surname>Wang</surname><given-names>A.H.</given-names></name></person-group><article-title>Structural basis of mercury- and zinc-conjugated complexes as SARS-CoV 3C-like protease inhibitors</article-title><source>FEBS Lett</source><volume>581</volume><year>2007</year><fpage>5454</fpage><lpage>5458</lpage><pub-id pub-id-type="pmid">17981158</pub-id></element-citation></ref><ref id="bib0140"><label>28</label><element-citation publication-type="journal" id="sbref0140"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C.Y.</given-names></name><name><surname>Jan</surname><given-names>J.T.</given-names></name><name><surname>Ma</surname><given-names>S.H.</given-names></name><name><surname>Kuo</surname><given-names>C.J.</given-names></name><name><surname>Juan</surname><given-names>H.F.</given-names></name><name><surname>Cheng</surname><given-names>Y.S.</given-names></name><name><surname>Hsu</surname><given-names>H.H.</given-names></name><name><surname>Huang</surname><given-names>H.C.</given-names></name><name><surname>Wu</surname><given-names>D.</given-names></name><name><surname>Brik</surname><given-names>A.</given-names></name></person-group><article-title>Small molecules targeting severe acute respiratory syndrome human coronavirus</article-title><source>Proc Natl Acad Sci U S A</source><volume>101</volume><year>2004</year><fpage>10012</fpage><lpage>10017</lpage><pub-id pub-id-type="pmid">15226499</pub-id></element-citation></ref><ref id="bib0145"><label>29</label><element-citation publication-type="journal" id="sbref0145"><person-group person-group-type="author"><name><surname>Shao</surname><given-names>Y.M.</given-names></name><name><surname>Yang</surname><given-names>W.B.</given-names></name><name><surname>Peng</surname><given-names>H.P.</given-names></name><name><surname>Hsu</surname><given-names>M.F.</given-names></name><name><surname>Tsai</surname><given-names>K.C.</given-names></name><name><surname>Kuo</surname><given-names>T.H.</given-names></name><name><surname>Wang</surname><given-names>A.H.</given-names></name><name><surname>Liang</surname><given-names>P.H.</given-names></name><name><surname>Lin</surname><given-names>C.H.</given-names></name><name><surname>Yang</surname><given-names>A.S.</given-names></name></person-group><article-title>Structure-based design and synthesis of highly potent SARS-CoV 3CL protease inhibitors</article-title><source>Chembiochem</source><volume>8</volume><year>2007</year><fpage>1654</fpage><lpage>1657</lpage><pub-id pub-id-type="pmid">17722121</pub-id></element-citation></ref><ref id="bib0150"><label>30</label><element-citation publication-type="journal" id="sbref0150"><person-group person-group-type="author"><name><surname>Shie</surname><given-names>J.J.</given-names></name><name><surname>Fang</surname><given-names>J.M.</given-names></name><name><surname>Kuo</surname><given-names>T.H.</given-names></name><name><surname>Kuo</surname><given-names>C.J.</given-names></name><name><surname>Liang</surname><given-names>P.H.</given-names></name><name><surname>Huang</surname><given-names>H.J.</given-names></name><name><surname>Wu</surname><given-names>Y.T.</given-names></name><name><surname>Jan</surname><given-names>J.T.</given-names></name><name><surname>Cheng</surname><given-names>Y.S.</given-names></name><name><surname>Wong</surname><given-names>C.H.</given-names></name></person-group><article-title>Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic alpha,beta-unsaturated esters</article-title><source>Bioorg Med Chem</source><volume>13</volume><year>2005</year><fpage>5240</fpage><lpage>5252</lpage><pub-id pub-id-type="pmid">15994085</pub-id></element-citation></ref><ref id="bib0155"><label>31</label><element-citation publication-type="journal" id="sbref0155"><person-group person-group-type="author"><name><surname>Shie</surname><given-names>J.J.</given-names></name><name><surname>Fang</surname><given-names>J.M.</given-names></name><name><surname>Kuo</surname><given-names>C.J.</given-names></name><name><surname>Kuo</surname><given-names>T.H.</given-names></name><name><surname>Liang</surname><given-names>P.H.</given-names></name><name><surname>Huang</surname><given-names>H.J.</given-names></name><name><surname>Yang</surname><given-names>W.B.</given-names></name><name><surname>Lin</surname><given-names>C.H.</given-names></name><name><surname>Chen</surname><given-names>J.L.</given-names></name><name><surname>Wu</surname><given-names>Y.T.</given-names></name></person-group><article-title>Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease</article-title><source>J Med Chem</source><volume>48</volume><year>2005</year><fpage>4469</fpage><lpage>4473</lpage><pub-id pub-id-type="pmid">15974598</pub-id></element-citation></ref><ref id="bib0160"><label>32</label><element-citation publication-type="journal" id="sbref0160"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C.Y.</given-names></name><name><surname>King</surname><given-names>K.Y.</given-names></name><name><surname>Kuo</surname><given-names>C.J.</given-names></name><name><surname>Fang</surname><given-names>J.M.</given-names></name><name><surname>Wu</surname><given-names>Y.T.</given-names></name><name><surname>Ho</surname><given-names>M.Y.</given-names></name><name><surname>Liao</surname><given-names>C.L.</given-names></name><name><surname>Shie</surname><given-names>J.J.</given-names></name><name><surname>Liang</surname><given-names>P.H.</given-names></name><name><surname>Wong</surname><given-names>C.H.</given-names></name></person-group><article-title>Stable benzotriazole esters as mechanism-based inactivators of the severe acute respiratory syndrome 3CL protease</article-title><source>Chem Biol</source><volume>13</volume><year>2006</year><fpage>261</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">16638531</pub-id></element-citation></ref><ref id="bib0165"><label>33</label><element-citation publication-type="journal" id="sbref0165"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>K.C.</given-names></name><name><surname>Chen</surname><given-names>S.Y.</given-names></name><name><surname>Liang</surname><given-names>P.H.</given-names></name><name><surname>Lu</surname><given-names>I.L.</given-names></name><name><surname>Mahindroo</surname><given-names>N.</given-names></name><name><surname>Hsieh</surname><given-names>H.P.</given-names></name><name><surname>Chao</surname><given-names>Y.S.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>D.</given-names></name><name><surname>Lien</surname><given-names>W.</given-names></name></person-group><article-title>Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies</article-title><source>J Med Chem</source><volume>49</volume><year>2006</year><fpage>3485</fpage><lpage>3495</lpage><pub-id pub-id-type="pmid">16759091</pub-id></element-citation></ref><ref id="bib0170"><label>34</label><element-citation publication-type="journal" id="sbref0170"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>I.L.</given-names></name><name><surname>Huang</surname><given-names>C.F.</given-names></name><name><surname>Peng</surname><given-names>Y.H.</given-names></name><name><surname>Lin</surname><given-names>Y.T.</given-names></name><name><surname>Hsieh</surname><given-names>H.P.</given-names></name><name><surname>Chen</surname><given-names>C.T.</given-names></name><name><surname>Lien</surname><given-names>T.W.</given-names></name><name><surname>Lee</surname><given-names>H.J.</given-names></name><name><surname>Mahindroo</surname><given-names>N.</given-names></name><name><surname>Prakash</surname><given-names>E.</given-names></name></person-group><article-title>Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities</article-title><source>J Med Chem</source><volume>49</volume><year>2006</year><fpage>2703</fpage><lpage>2712</lpage><pub-id pub-id-type="pmid">16640330</pub-id></element-citation></ref><ref id="bib0175"><label>35</label><element-citation publication-type="journal" id="sbref0175"><person-group person-group-type="author"><name><surname>Shao</surname><given-names>Y.M.</given-names></name><name><surname>Yang</surname><given-names>W.B.</given-names></name><name><surname>Kuo</surname><given-names>T.H.</given-names></name><name><surname>Tsai</surname><given-names>K.C.</given-names></name><name><surname>Lin</surname><given-names>C.H.</given-names></name><name><surname>Yang</surname><given-names>A.S.</given-names></name><name><surname>Liang</surname><given-names>P.H.</given-names></name><name><surname>Wong</surname><given-names>C.H.</given-names></name></person-group><article-title>Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease</article-title><source>Bioorg Med Chem</source><volume>16</volume><year>2008</year><fpage>4652</fpage><lpage>4660</lpage><pub-id pub-id-type="pmid">18329272</pub-id></element-citation></ref><ref id="bib0180"><label>36</label><element-citation publication-type="journal" id="sbref0180"><person-group person-group-type="author"><name><surname>Ramajayam</surname><given-names>R.</given-names></name><name><surname>Tan</surname><given-names>K.P.</given-names></name><name><surname>Liu</surname><given-names>H.G.</given-names></name><name><surname>Liang</surname><given-names>P.H.</given-names></name></person-group><article-title>Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease</article-title><source>Bioorg Med Chem Lett</source><volume>20</volume><year>2010</year><fpage>3569</fpage><lpage>3572</lpage><pub-id pub-id-type="pmid">20494577</pub-id></element-citation></ref><ref id="bib0185"><label>37</label><element-citation publication-type="journal" id="sbref0185"><person-group person-group-type="author"><name><surname>Harcourt</surname><given-names>B.H.</given-names></name><name><surname>Jukneliene</surname><given-names>D.</given-names></name><name><surname>Kanjanahaluethai</surname><given-names>A.</given-names></name><name><surname>Bechill</surname><given-names>J.</given-names></name><name><surname>Severson</surname><given-names>K.M.</given-names></name><name><surname>Smith</surname><given-names>C.M.</given-names></name><name><surname>Rota</surname><given-names>P.A.</given-names></name><name><surname>Baker</surname><given-names>S.C.</given-names></name></person-group><article-title>Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity</article-title><source>J Virol</source><volume>78</volume><year>2004</year><fpage>13600</fpage><lpage>13612</lpage><pub-id pub-id-type="pmid">15564471</pub-id></element-citation></ref><ref id="bib0190"><label>38</label><element-citation publication-type="journal" id="sbref0190"><person-group person-group-type="author"><name><surname>Barretto</surname><given-names>N.</given-names></name><name><surname>Jukneliene</surname><given-names>D.</given-names></name><name><surname>Ratia</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Mesecar</surname><given-names>A.D.</given-names></name><name><surname>Baker</surname><given-names>S.C.</given-names></name></person-group><article-title>The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity</article-title><source>J Virol</source><volume>79</volume><year>2005</year><fpage>15189</fpage><lpage>15198</lpage><pub-id pub-id-type="pmid">16306590</pub-id></element-citation></ref><ref id="bib0195"><label>39</label><element-citation publication-type="journal" id="sbref0195"><person-group person-group-type="author"><name><surname>Frieman</surname><given-names>M.</given-names></name><name><surname>Basu</surname><given-names>D.</given-names></name><name><surname>Matthews</surname><given-names>K.</given-names></name><name><surname>Taylor</surname><given-names>J.</given-names></name><name><surname>Jones</surname><given-names>G.</given-names></name><name><surname>Pickles</surname><given-names>R.</given-names></name><name><surname>Baric</surname><given-names>R.</given-names></name><name><surname>Engel</surname><given-names>D.A.</given-names></name></person-group><article-title>Yeast based small molecule screen for inhibitors of SARS-CoV</article-title><source>PLoS One</source><volume>6</volume><year>2011</year><fpage>e28479</fpage><pub-id pub-id-type="pmid">22164298</pub-id></element-citation></ref><ref id="bib0200"><label>40</label><element-citation publication-type="journal" id="sbref0200"><person-group person-group-type="author"><name><surname>Gorbalenya</surname><given-names>A.E.K.E.</given-names></name></person-group><article-title>Helicases: amino acid sequence comparisons and structure function relationships</article-title><source>Curr Opin Struct Biol</source><volume>3</volume><year>1993</year><fpage>419</fpage><lpage>429</lpage></element-citation></ref><ref id="bib0205"><label>41&#x02022;&#x02022;</label><element-citation publication-type="journal" id="sbref0205"><person-group person-group-type="author"><name><surname>Adedeji</surname><given-names>A.O.</given-names></name><name><surname>Marchand</surname><given-names>B.</given-names></name><name><surname>Te Velthuis</surname><given-names>A.J.</given-names></name><name><surname>Snijder</surname><given-names>E.J.</given-names></name><name><surname>Weiss</surname><given-names>S.</given-names></name><name><surname>Eoff</surname><given-names>R.L.</given-names></name><name><surname>Singh</surname><given-names>K.</given-names></name><name><surname>Sarafianos</surname><given-names>S.G.</given-names></name></person-group><article-title>Mechanism of nucleic acid unwinding by SARS-CoV helicase</article-title><source>PLoS One</source><volume>7</volume><year>2012</year><fpage>e36521</fpage><pub-id pub-id-type="pmid">22615777</pub-id></element-citation><note><p>This manuscript demonstrates the detailed biochemical mechanism of nuclei acid unwinding by SARS-CoV helicase.</p></note></ref><ref id="bib0210"><label>42</label><element-citation publication-type="journal" id="sbref0210"><person-group person-group-type="author"><name><surname>Paolini</surname><given-names>C.</given-names></name><name><surname>De Francesco</surname><given-names>R.</given-names></name><name><surname>Gallinari</surname><given-names>P.</given-names></name></person-group><article-title>Enzymatic properties of hepatitis C virus NS3-associated helicase</article-title><source>J Gen Virol</source><volume>81</volume><year>2000</year><fpage>1335</fpage><lpage>1345</lpage><pub-id pub-id-type="pmid">10769077</pub-id></element-citation></ref><ref id="bib0215"><label>43</label><element-citation publication-type="journal" id="sbref0215"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M.K.</given-names></name><name><surname>Yu</surname><given-names>M.S.</given-names></name><name><surname>Park</surname><given-names>H.R.</given-names></name><name><surname>Kim</surname><given-names>K.B.</given-names></name><name><surname>Lee</surname><given-names>C.</given-names></name><name><surname>Cho</surname><given-names>S.Y.</given-names></name><name><surname>Kang</surname><given-names>J.</given-names></name><name><surname>Yoon</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>D.E.</given-names></name><name><surname>Choo</surname><given-names>H.</given-names></name></person-group><article-title>2,6-Bis-arylmethyloxy-5-hydroxychromones with antiviral activity against both hepatitis C virus (HCV) and SARS-associated coronavirus (SCV)</article-title><source>Eur J Med Chem</source><volume>46</volume><year>2011</year><fpage>5698</fpage><lpage>5704</lpage><pub-id pub-id-type="pmid">21925774</pub-id></element-citation></ref><ref id="bib0220"><label>44</label><element-citation publication-type="journal" id="sbref0220"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>C.</given-names></name><name><surname>Lee</surname><given-names>J.M.</given-names></name><name><surname>Lee</surname><given-names>N.R.</given-names></name><name><surname>Jin</surname><given-names>B.S.</given-names></name><name><surname>Jang</surname><given-names>K.J.</given-names></name><name><surname>Kim</surname><given-names>D.E.</given-names></name><name><surname>Jeong</surname><given-names>Y.J.</given-names></name><name><surname>Chong</surname><given-names>Y.</given-names></name></person-group><article-title>Aryl diketoacids (ADK) selectively inhibit duplex DNA-unwinding activity of SARS coronavirus NTPase/helicase</article-title><source>Bioorg Med Chem Lett</source><volume>19</volume><year>2009</year><fpage>1636</fpage><lpage>1638</lpage><pub-id pub-id-type="pmid">19233643</pub-id></element-citation></ref><ref id="bib0225"><label>45</label><element-citation publication-type="journal" id="sbref0225"><person-group person-group-type="author"><name><surname>Tanner</surname><given-names>J.A.</given-names></name><name><surname>Zheng</surname><given-names>B.J.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Watt</surname><given-names>R.M.</given-names></name><name><surname>Jiang</surname><given-names>J.Q.</given-names></name><name><surname>Wong</surname><given-names>K.L.</given-names></name><name><surname>Lin</surname><given-names>Y.P.</given-names></name><name><surname>Lu</surname><given-names>L.Y.</given-names></name><name><surname>He</surname><given-names>M.L.</given-names></name><name><surname>Kung</surname><given-names>H.F.</given-names></name></person-group><article-title>The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus</article-title><source>Chem Biol</source><volume>12</volume><year>2005</year><fpage>303</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">15797214</pub-id></element-citation></ref><ref id="bib0230"><label>46</label><element-citation publication-type="journal" id="sbref0230"><person-group person-group-type="author"><name><surname>Adedeji</surname><given-names>A.O.</given-names></name><name><surname>Sarafianos</surname><given-names>S.G.</given-names></name></person-group><article-title>Future treatment strategies for novel Middle East respiratory syndrome coronavirus infection</article-title><source>Future Med Chem</source><volume>5</volume><year>2013</year><fpage>2119</fpage><lpage>2122</lpage><pub-id pub-id-type="pmid">24261888</pub-id></element-citation></ref><ref id="bib0235"><label>47</label><element-citation publication-type="journal" id="sbref0235"><person-group person-group-type="author"><name><surname>Adedeji</surname><given-names>A.O.</given-names></name><name><surname>Singh</surname><given-names>K.</given-names></name><name><surname>Kassim</surname><given-names>A.</given-names></name><name><surname>Coleman</surname><given-names>C.M.</given-names></name><name><surname>Elliott</surname><given-names>R.</given-names></name><name><surname>Weiss</surname><given-names>S.R.</given-names></name><name><surname>Frieman</surname><given-names>M.B.</given-names></name><name><surname>Sarafianos</surname><given-names>S.G.</given-names></name></person-group><article-title>Evaluation of SSYA10-001 as a replication inhibitor of SARS, MHV and MERS coronaviruses</article-title><source>Antimicrob Agents Chemother</source><volume>58</volume><issue>8</issue><year>2014</year><pub-id pub-id-type="doi">10.1128/AAC.02994-14</pub-id><comment>PMID: 24841268</comment></element-citation></ref><ref id="bib0240"><label>48</label><element-citation publication-type="journal" id="sbref0240"><person-group person-group-type="author"><name><surname>Bupp</surname><given-names>K.</given-names></name><name><surname>Roth</surname><given-names>M.J.</given-names></name></person-group><article-title>Alteration and analyses of viral entry with library-derived peptides</article-title><source>Adv Virus Res</source><volume>65</volume><year>2005</year><fpage>147</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">16387196</pub-id></element-citation></ref><ref id="bib0245"><label>49</label><element-citation publication-type="journal" id="sbref0245"><person-group person-group-type="author"><name><surname>Douglas</surname><given-names>J.L.</given-names></name><name><surname>Panis</surname><given-names>M.L.</given-names></name><name><surname>Ho</surname><given-names>E.</given-names></name><name><surname>Lin</surname><given-names>K.Y.</given-names></name><name><surname>Krawczyk</surname><given-names>S.H.</given-names></name><name><surname>Grant</surname><given-names>D.M.</given-names></name><name><surname>Cai</surname><given-names>R.</given-names></name><name><surname>Swaminathan</surname><given-names>S.</given-names></name><name><surname>Cihlar</surname><given-names>T.</given-names></name></person-group><article-title>Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein</article-title><source>J Virol</source><volume>77</volume><year>2003</year><fpage>5054</fpage><lpage>5064</lpage><pub-id pub-id-type="pmid">12692208</pub-id></element-citation></ref><ref id="bib0250"><label>50</label><element-citation publication-type="journal" id="sbref0250"><person-group person-group-type="author"><name><surname>Razinkov</surname><given-names>V.</given-names></name><name><surname>Gazumyan</surname><given-names>A.</given-names></name><name><surname>Nikitenko</surname><given-names>A.</given-names></name><name><surname>Ellestad</surname><given-names>G.</given-names></name><name><surname>Krishnamurthy</surname><given-names>G.</given-names></name></person-group><article-title>RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein</article-title><source>Chem Biol</source><volume>8</volume><year>2001</year><fpage>645</fpage><lpage>659</lpage><pub-id pub-id-type="pmid">11451666</pub-id></element-citation></ref><ref id="bib0255"><label>51</label><element-citation publication-type="journal" id="sbref0255"><person-group person-group-type="author"><name><surname>Lieberman-Blum</surname><given-names>S.S.</given-names></name><name><surname>Fung</surname><given-names>H.B.</given-names></name><name><surname>Bandres</surname><given-names>J.C.</given-names></name></person-group><article-title>Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection</article-title><source>Clin Ther</source><volume>30</volume><year>2008</year><fpage>1228</fpage><lpage>1250</lpage><pub-id pub-id-type="pmid">18691983</pub-id></element-citation></ref><ref id="bib0260"><label>52</label><element-citation publication-type="journal" id="sbref0260"><person-group person-group-type="author"><name><surname>MacArthur</surname><given-names>R.D.</given-names></name><name><surname>Novak</surname><given-names>R.M.</given-names></name></person-group><article-title>Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents</article-title><source>Clin Infect Dis</source><volume>47</volume><year>2008</year><fpage>236</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">18532888</pub-id></element-citation></ref><ref id="bib0265"><label>53</label><element-citation publication-type="journal" id="sbref0265"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>A.</given-names></name><name><surname>Armour</surname><given-names>D.</given-names></name></person-group><article-title>The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS</article-title><source>Prog Med Chem</source><volume>43</volume><year>2005</year><fpage>239</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">15850827</pub-id></element-citation></ref><ref id="bib0270"><label>54</label><element-citation publication-type="journal" id="sbref0270"><person-group person-group-type="author"><name><surname>Anonymous</surname></name></person-group><article-title>Pentafuside. DP 178, T 20</article-title><source>Drugs R D</source><volume>2</volume><year>1999</year><fpage>347</fpage><lpage>349</lpage><pub-id pub-id-type="pmid">10728478</pub-id></element-citation></ref><ref id="bib0275"><label>55</label><element-citation publication-type="journal" id="sbref0275"><person-group person-group-type="author"><name><surname>Berkhout</surname><given-names>B.</given-names></name><name><surname>Eggink</surname><given-names>D.</given-names></name><name><surname>Sanders</surname><given-names>R.W.</given-names></name></person-group><article-title>Is there a future for antiviral fusion inhibitors?</article-title><source>Curr Opin Virol</source><volume>2</volume><year>2012</year><fpage>50</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">22440966</pub-id></element-citation></ref><ref id="bib0280"><label>56</label><element-citation publication-type="journal" id="sbref0280"><person-group person-group-type="author"><name><surname>Derdeyn</surname><given-names>C.A.</given-names></name><name><surname>Decker</surname><given-names>J.M.</given-names></name><name><surname>Sfakianos</surname><given-names>J.N.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>W.A.</given-names></name><name><surname>Ratner</surname><given-names>L.</given-names></name><name><surname>Kappes</surname><given-names>J.C.</given-names></name><name><surname>Shaw</surname><given-names>G.M.</given-names></name><name><surname>Hunter</surname><given-names>E.</given-names></name></person-group><article-title>Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120</article-title><source>J Virol</source><volume>74</volume><year>2000</year><fpage>8358</fpage><lpage>8367</lpage><pub-id pub-id-type="pmid">10954535</pub-id></element-citation></ref><ref id="bib0285"><label>57</label><element-citation publication-type="journal" id="sbref0285"><person-group person-group-type="author"><name><surname>Hartt</surname><given-names>J.K.</given-names></name><name><surname>Liang</surname><given-names>T.</given-names></name><name><surname>Sahagun-Ruiz</surname><given-names>A.</given-names></name><name><surname>Wang</surname><given-names>J.M.</given-names></name><name><surname>Gao</surname><given-names>J.L.</given-names></name><name><surname>Murphy</surname><given-names>P.M.</given-names></name></person-group><article-title>The HIV-1 cell entry inhibitor T-20 potently chemoattracts neutrophils by specifically activating the N-formylpeptide receptor</article-title><source>Biochem Biophys Res Commun</source><volume>272</volume><year>2000</year><fpage>699</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">10860818</pub-id></element-citation></ref><ref id="bib0290"><label>58</label><element-citation publication-type="journal" id="sbref0290"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>M.D.</given-names></name><name><surname>Hazuda</surname><given-names>D.J.</given-names></name></person-group><article-title>HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications</article-title><source>Drug Resist Updat</source><volume>7</volume><year>2004</year><fpage>89</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">15158765</pub-id></element-citation></ref><ref id="bib0295"><label>59</label><element-citation publication-type="journal" id="sbref0295"><person-group person-group-type="author"><name><surname>Naito</surname><given-names>T.</given-names></name><name><surname>Izumi</surname><given-names>K.</given-names></name><name><surname>Kodama</surname><given-names>E.</given-names></name><name><surname>Sakagami</surname><given-names>Y.</given-names></name><name><surname>Kajiwara</surname><given-names>K.</given-names></name><name><surname>Nishikawa</surname><given-names>H.</given-names></name><name><surname>Watanabe</surname><given-names>K.</given-names></name><name><surname>Sarafianos</surname><given-names>S.G.</given-names></name><name><surname>Oishi</surname><given-names>S.</given-names></name><name><surname>Fujii</surname><given-names>N.</given-names></name></person-group><article-title>SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide</article-title><source>Antimicrob Agents Chemother</source><volume>53</volume><year>2009</year><fpage>1013</fpage><lpage>1018</lpage><pub-id pub-id-type="pmid">19114674</pub-id></element-citation></ref><ref id="bib0300"><label>60</label><element-citation publication-type="journal" id="sbref0300"><person-group person-group-type="author"><name><surname>Eda</surname><given-names>Y.</given-names></name><name><surname>Murakami</surname><given-names>T.</given-names></name><name><surname>Ami</surname><given-names>Y.</given-names></name><name><surname>Nakasone</surname><given-names>T.</given-names></name><name><surname>Takizawa</surname><given-names>M.</given-names></name><name><surname>Someya</surname><given-names>K.</given-names></name><name><surname>Kaizu</surname><given-names>M.</given-names></name><name><surname>Izumi</surname><given-names>Y.</given-names></name><name><surname>Yoshino</surname><given-names>N.</given-names></name><name><surname>Matsushita</surname><given-names>S.</given-names></name></person-group><article-title>Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection</article-title><source>J Virol</source><volume>80</volume><year>2006</year><fpage>5563</fpage><lpage>5570</lpage><pub-id pub-id-type="pmid">16699037</pub-id></element-citation></ref><ref id="bib0305"><label>61</label><element-citation publication-type="journal" id="sbref0305"><person-group person-group-type="author"><name><surname>Matsushita</surname><given-names>S.</given-names></name><name><surname>Takahama</surname><given-names>S.</given-names></name><name><surname>Shibata</surname><given-names>J.</given-names></name><name><surname>Kimura</surname><given-names>T.</given-names></name><name><surname>Shiozaki</surname><given-names>K.</given-names></name><name><surname>Eda</surname><given-names>Y.</given-names></name><name><surname>Koito</surname><given-names>A.</given-names></name><name><surname>Murakami</surname><given-names>T.</given-names></name><name><surname>Yoshimura</surname><given-names>K.</given-names></name></person-group><article-title>Ex vivo neutralization of HIV-1 quasi-species by a broadly reactive humanized monoclonal antibody KD-247</article-title><source>Hum Antibodies</source><volume>14</volume><year>2005</year><fpage>81</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">16720978</pub-id></element-citation></ref><ref id="bib0310"><label>62</label><element-citation publication-type="journal" id="sbref0310"><person-group person-group-type="author"><name><surname>Cilliers</surname><given-names>T.</given-names></name><name><surname>Willey</surname><given-names>S.</given-names></name><name><surname>Sullivan</surname><given-names>W.M.</given-names></name><name><surname>Patience</surname><given-names>T.</given-names></name><name><surname>Pugach</surname><given-names>P.</given-names></name><name><surname>Coetzer</surname><given-names>M.</given-names></name><name><surname>Papathanasopoulos</surname><given-names>M.</given-names></name><name><surname>Moore</surname><given-names>J.P.</given-names></name><name><surname>Trkola</surname><given-names>A.</given-names></name><name><surname>Clapham</surname><given-names>P.</given-names></name></person-group><article-title>Use of alternate coreceptors on primary cells by two HIV-1 isolates</article-title><source>Virology</source><volume>339</volume><year>2005</year><fpage>136</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">15992849</pub-id></element-citation></ref><ref id="bib0315"><label>63</label><element-citation publication-type="journal" id="sbref0315"><person-group person-group-type="author"><name><surname>Dau</surname><given-names>B.</given-names></name><name><surname>Holodniy</surname><given-names>M.</given-names></name></person-group><article-title>Novel targets for antiretroviral therapy: clinical progress to date</article-title><source>Drugs</source><volume>69</volume><year>2009</year><fpage>31</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">19192935</pub-id></element-citation></ref><ref id="bib0320"><label>64</label><element-citation publication-type="journal" id="sbref0320"><person-group person-group-type="author"><name><surname>Perlman</surname><given-names>S.</given-names></name><name><surname>Netland</surname><given-names>J.</given-names></name></person-group><article-title>Coronaviruses post-SARS: update on replication and pathogenesis</article-title><source>Nat Rev Microbiol</source><volume>7</volume><year>2009</year><fpage>439</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">19430490</pub-id></element-citation></ref><ref id="bib0325"><label>65</label><element-citation publication-type="journal" id="sbref0325"><person-group person-group-type="author"><name><surname>Bosch</surname><given-names>B.J.</given-names></name><name><surname>van der Zee</surname><given-names>R.</given-names></name><name><surname>de Haan</surname><given-names>C.A.</given-names></name><name><surname>Rottier</surname><given-names>P.J.</given-names></name></person-group><article-title>The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex</article-title><source>J Virol</source><volume>77</volume><year>2003</year><fpage>8801</fpage><lpage>8811</lpage><pub-id pub-id-type="pmid">12885899</pub-id></element-citation></ref><ref id="bib0330"><label>66</label><element-citation publication-type="journal" id="sbref0330"><person-group person-group-type="author"><name><surname>Hofmann</surname><given-names>H.</given-names></name><name><surname>Geier</surname><given-names>M.</given-names></name><name><surname>Marzi</surname><given-names>A.</given-names></name><name><surname>Krumbiegel</surname><given-names>M.</given-names></name><name><surname>Peipp</surname><given-names>M.</given-names></name><name><surname>Fey</surname><given-names>G.H.</given-names></name><name><surname>Gramberg</surname><given-names>T.</given-names></name><name><surname>Pohlmann</surname><given-names>S.</given-names></name></person-group><article-title>Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor</article-title><source>Biochem Biophys Res Commun</source><volume>319</volume><year>2004</year><fpage>1216</fpage><lpage>1221</lpage><pub-id pub-id-type="pmid">15194496</pub-id></element-citation></ref><ref id="bib0335"><label>67&#x02022;&#x02022;</label><element-citation publication-type="journal" id="sbref0335"><person-group person-group-type="author"><name><surname>Simmons</surname><given-names>G.</given-names></name><name><surname>Gosalia</surname><given-names>D.N.</given-names></name><name><surname>Rennekamp</surname><given-names>A.J.</given-names></name><name><surname>Reeves</surname><given-names>J.D.</given-names></name><name><surname>Diamond</surname><given-names>S.L.</given-names></name><name><surname>Bates</surname><given-names>P.</given-names></name></person-group><article-title>Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry</article-title><source>Proc Natl Acad Sci U S A</source><volume>102</volume><year>2005</year><fpage>11876</fpage><lpage>11881</lpage><pub-id pub-id-type="pmid">16081529</pub-id></element-citation><note><p>First report that demonstrates cathepsin L is required for SARS-CoV entry, and therefore stands as a potential antiviral target.</p></note></ref><ref id="bib0340"><label>68</label><element-citation publication-type="journal" id="sbref0340"><person-group person-group-type="author"><name><surname>Tripet</surname><given-names>B.</given-names></name><name><surname>Howard</surname><given-names>M.W.</given-names></name><name><surname>Jobling</surname><given-names>M.</given-names></name><name><surname>Holmes</surname><given-names>R.K.</given-names></name><name><surname>Holmes</surname><given-names>K.V.</given-names></name><name><surname>Hodges</surname><given-names>R.S.</given-names></name></person-group><article-title>Structural characterization of the SARS-coronavirus spike S fusion protein core</article-title><source>J Biol Chem</source><volume>279</volume><year>2004</year><fpage>20836</fpage><lpage>20849</lpage><pub-id pub-id-type="pmid">14996844</pub-id></element-citation></ref><ref id="bib0345"><label>69&#x02022;&#x02022;</label><element-citation publication-type="journal" id="sbref0345"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>S.K.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Moore</surname><given-names>M.J.</given-names></name><name><surname>Choe</surname><given-names>H.</given-names></name><name><surname>Farzan</surname><given-names>M.</given-names></name></person-group><article-title>A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2</article-title><source>J Biol Chem</source><volume>279</volume><year>2004</year><fpage>3197</fpage><lpage>3201</lpage><pub-id pub-id-type="pmid">14670965</pub-id></element-citation><note><p>Identification of receptor binding domain within the SARS-CoV envelope.</p></note></ref><ref id="bib0350"><label>70</label><element-citation publication-type="journal" id="sbref0350"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z.Y.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Ganesh</surname><given-names>L.</given-names></name><name><surname>Leung</surname><given-names>K.</given-names></name><name><surname>Kong</surname><given-names>W.P.</given-names></name><name><surname>Schwartz</surname><given-names>O.</given-names></name><name><surname>Subbarao</surname><given-names>K.</given-names></name></person-group><article-title>Nabel GJ: pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN</article-title><source>J Virol</source><volume>78</volume><year>2004</year><fpage>5642</fpage><lpage>5650</lpage><pub-id pub-id-type="pmid">15140961</pub-id></element-citation></ref><ref id="bib0355"><label>71</label><element-citation publication-type="journal" id="sbref0355"><person-group person-group-type="author"><name><surname>Dimitrov</surname><given-names>D.S.</given-names></name></person-group><article-title>The secret life of ACE2 as a receptor for the SARS virus</article-title><source>Cell</source><volume>115</volume><year>2003</year><fpage>652</fpage><lpage>653</lpage><pub-id pub-id-type="pmid">14675530</pub-id></element-citation></ref><ref id="bib0360"><label>72</label><element-citation publication-type="journal" id="sbref0360"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>X.</given-names></name><name><surname>Chakraborti</surname><given-names>S.</given-names></name><name><surname>Dimitrov</surname><given-names>A.S.</given-names></name><name><surname>Gramatikoff</surname><given-names>K.</given-names></name><name><surname>Dimitrov</surname><given-names>D.S.</given-names></name></person-group><article-title>The SARS-CoV S glycoprotein: expression and functional characterization</article-title><source>Biochem Biophys Res Commun</source><volume>312</volume><year>2003</year><fpage>1159</fpage><lpage>1164</lpage><pub-id pub-id-type="pmid">14651994</pub-id></element-citation></ref><ref id="bib0365"><label>73</label><element-citation publication-type="journal" id="sbref0365"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>P.P.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Kaletsky</surname><given-names>R.L.</given-names></name><name><surname>Myers</surname><given-names>M.C.</given-names></name><name><surname>Purvis</surname><given-names>J.E.</given-names></name><name><surname>Jing</surname><given-names>H.</given-names></name><name><surname>Huryn</surname><given-names>D.M.</given-names></name><name><surname>Greenbaum</surname><given-names>D.C.</given-names></name><name><surname>Smith</surname><given-names>A.B.</given-names><suffix>III</suffix></name><name><surname>Bates</surname><given-names>P.</given-names></name></person-group><article-title>A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells</article-title><source>Mol Pharmacol</source><volume>78</volume><year>2010</year><fpage>319</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">20466822</pub-id></element-citation></ref><ref id="bib0370"><label>74</label><element-citation publication-type="journal" id="sbref0370"><person-group person-group-type="author"><name><surname>Struck</surname><given-names>A.W.</given-names></name><name><surname>Axmann</surname><given-names>M.</given-names></name><name><surname>Pfefferle</surname><given-names>S.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name><name><surname>Meyer</surname><given-names>B.</given-names></name></person-group><article-title>A hexapeptide of the receptor-binding domain of SARS corona virus spike protein blocks viral entry into host cells via the human receptor ACE2</article-title><source>Antiviral Res</source><volume>94</volume><year>2012</year><fpage>288</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">22265858</pub-id></element-citation></ref><ref id="bib0375"><label>75</label><element-citation publication-type="journal" id="sbref0375"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Agudelo</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>K.</given-names></name><name><surname>Goetz</surname><given-names>D.H.</given-names></name><name><surname>Hansell</surname><given-names>E.</given-names></name><name><surname>Chen</surname><given-names>Y.T.</given-names></name><name><surname>Roush</surname><given-names>W.R.</given-names></name><name><surname>McKerrow</surname><given-names>J.</given-names></name><name><surname>Craik</surname><given-names>C.S.</given-names></name><name><surname>Amberg</surname><given-names>S.M.</given-names></name></person-group><article-title>Inhibitors of SARS-CoV entry&#x000a0;&#x02014;&#x000a0;identification using an internally-controlled dual envelope pseudovirion assay</article-title><source>Antiviral Res</source><volume>92</volume><year>2011</year><fpage>187</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">21820471</pub-id></element-citation></ref><ref id="bib0380"><label>76&#x02022;&#x02022;</label><element-citation publication-type="journal" id="sbref0380"><person-group person-group-type="author"><name><surname>Simmons</surname><given-names>G.</given-names></name><name><surname>Reeves</surname><given-names>J.D.</given-names></name><name><surname>Rennekamp</surname><given-names>A.J.</given-names></name><name><surname>Amberg</surname><given-names>S.M.</given-names></name><name><surname>Piefer</surname><given-names>A.J.</given-names></name><name><surname>Bates</surname><given-names>P.</given-names></name></person-group><article-title>Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry</article-title><source>Proc Natl Acad Sci U S A</source><volume>101</volume><year>2004</year><fpage>4240</fpage><lpage>4245</lpage><pub-id pub-id-type="pmid">15010527</pub-id></element-citation><note><p>Development of SARS-pseudotyped virus to study the mechanism of viral entry and possible antiviral targets.</p></note></ref><ref id="bib0385"><label>77&#x02022;&#x02022;</label><element-citation publication-type="journal" id="sbref0385"><person-group person-group-type="author"><name><surname>Adedeji</surname><given-names>A.O.</given-names></name><name><surname>Severson</surname><given-names>W.</given-names></name><name><surname>Jonsson</surname><given-names>C.</given-names></name><name><surname>Singh</surname><given-names>K.</given-names></name><name><surname>Weiss</surname><given-names>S.R.</given-names></name><name><surname>Sarafianos</surname><given-names>S.G.</given-names></name></person-group><article-title>Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms</article-title><source>J Virol</source><volume>87</volume><year>2013</year><fpage>8017</fpage><lpage>8028</lpage><pub-id pub-id-type="pmid">23678171</pub-id></element-citation><note><p>This study reveals the discovery of three small molecule inhibitors of SARS-CoV entry with distinct mechanisms of inhibition.</p></note></ref><ref id="bib0390"><label>78</label><element-citation publication-type="journal" id="sbref0390"><person-group person-group-type="author"><name><surname>Huentelman</surname><given-names>M.J.</given-names></name><name><surname>Zubcevic</surname><given-names>J.</given-names></name><name><surname>Hernandez Prada</surname><given-names>J.A.</given-names></name><name><surname>Xiao</surname><given-names>X.</given-names></name><name><surname>Dimitrov</surname><given-names>D.S.</given-names></name><name><surname>Raizada</surname><given-names>M.K.</given-names></name><name><surname>Ostrov</surname><given-names>D.A.</given-names></name></person-group><article-title>Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor</article-title><source>Hypertension</source><volume>44</volume><year>2004</year><fpage>903</fpage><lpage>906</lpage><pub-id pub-id-type="pmid">15492138</pub-id></element-citation></ref><ref id="bib0395"><label>79&#x02022;&#x02022;</label><element-citation publication-type="journal" id="sbref0395"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Moore</surname><given-names>M.J.</given-names></name><name><surname>Vasilieva</surname><given-names>N.</given-names></name><name><surname>Sui</surname><given-names>J.</given-names></name><name><surname>Wong</surname><given-names>S.K.</given-names></name><name><surname>Berne</surname><given-names>M.A.</given-names></name><name><surname>Somasundaran</surname><given-names>M.</given-names></name><name><surname>Sullivan</surname><given-names>J.L.</given-names></name><name><surname>Luzuriaga</surname><given-names>K.</given-names></name><name><surname>Greenough</surname><given-names>T.C.</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</article-title><source>Nature</source><volume>426</volume><year>2003</year><fpage>450</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">14647384</pub-id></element-citation><note><p>Identification of ACE2 as the receptor for SARS-CoV entry into permissive cells.</p></note></ref><ref id="bib0400"><label>80</label><element-citation publication-type="journal" id="sbref0400"><person-group person-group-type="author"><name><surname>Danilczyk</surname><given-names>U.</given-names></name><name><surname>Penninger</surname><given-names>J.M.</given-names></name></person-group><article-title>Angiotensin-converting enzyme II in the heart and the kidney</article-title><source>Circ Res</source><volume>98</volume><year>2006</year><fpage>463</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">16514079</pub-id></element-citation></ref><ref id="bib0405"><label>81</label><element-citation publication-type="journal" id="sbref0405"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>J.S.</given-names></name><name><surname>Chu</surname><given-names>C.M.</given-names></name><name><surname>Cheng</surname><given-names>V.C.</given-names></name><name><surname>Chan</surname><given-names>K.S.</given-names></name><name><surname>Hung</surname><given-names>I.F.</given-names></name><name><surname>Poon</surname><given-names>L.L.</given-names></name><name><surname>Law</surname><given-names>K.I.</given-names></name><name><surname>Tang</surname><given-names>B.S.</given-names></name><name><surname>Hon</surname><given-names>T.Y.</given-names></name><name><surname>Chan</surname><given-names>C.S.</given-names></name></person-group><article-title>Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study</article-title><source>Lancet</source><volume>361</volume><year>2003</year><fpage>1767</fpage><lpage>1772</lpage><pub-id pub-id-type="pmid">12781535</pub-id></element-citation></ref><ref id="bib0410"><label>82</label><element-citation publication-type="journal" id="sbref0410"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>J.J.</given-names></name><name><surname>Wu</surname><given-names>A.</given-names></name><name><surname>Joynt</surname><given-names>G.M.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name><name><surname>Lee</surname><given-names>N.</given-names></name><name><surname>Chan</surname><given-names>P.K.</given-names></name><name><surname>Cockram</surname><given-names>C.S.</given-names></name><name><surname>Ahuja</surname><given-names>A.T.</given-names></name><name><surname>Yu</surname><given-names>L.M.</given-names></name><name><surname>Wong</surname><given-names>V.W.</given-names></name></person-group><article-title>Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak</article-title><source>Thorax</source><volume>59</volume><year>2004</year><fpage>414</fpage><lpage>420</lpage><pub-id pub-id-type="pmid">15115870</pub-id></element-citation></ref><ref id="bib0415"><label>83</label><element-citation publication-type="journal" id="sbref0415"><person-group person-group-type="author"><name><surname>Booth</surname><given-names>C.M.</given-names></name><name><surname>Matukas</surname><given-names>L.M.</given-names></name><name><surname>Tomlinson</surname><given-names>G.A.</given-names></name><name><surname>Rachlis</surname><given-names>A.R.</given-names></name><name><surname>Rose</surname><given-names>D.B.</given-names></name><name><surname>Dwosh</surname><given-names>H.A.</given-names></name><name><surname>Walmsley</surname><given-names>S.L.</given-names></name><name><surname>Mazzulli</surname><given-names>T.</given-names></name><name><surname>Avendano</surname><given-names>M.</given-names></name><name><surname>Derkach</surname><given-names>P.</given-names></name></person-group><article-title>Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area</article-title><source>JAMA</source><volume>289</volume><year>2003</year><fpage>2801</fpage><lpage>2809</lpage><pub-id pub-id-type="pmid">12734147</pub-id></element-citation></ref><ref id="bib0420"><label>84</label><element-citation publication-type="journal" id="sbref0420"><person-group person-group-type="author"><name><surname>Loutfy</surname><given-names>M.R.</given-names></name><name><surname>Blatt</surname><given-names>L.M.</given-names></name><name><surname>Siminovitch</surname><given-names>K.A.</given-names></name><name><surname>Ward</surname><given-names>S.</given-names></name><name><surname>Wolff</surname><given-names>B.</given-names></name><name><surname>Lho</surname><given-names>H.</given-names></name><name><surname>Pham</surname><given-names>D.H.</given-names></name><name><surname>Deif</surname><given-names>H.</given-names></name><name><surname>LaMere</surname><given-names>E.A.</given-names></name><name><surname>Chang</surname><given-names>M.</given-names></name></person-group><article-title>Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study</article-title><source>JAMA</source><volume>290</volume><year>2003</year><fpage>3222</fpage><lpage>3228</lpage><pub-id pub-id-type="pmid">14693875</pub-id></element-citation></ref><ref id="bib0425"><label>85</label><element-citation publication-type="journal" id="sbref0425"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>C.M.</given-names></name><name><surname>Cheng</surname><given-names>V.C.</given-names></name><name><surname>Hung</surname><given-names>I.F.</given-names></name><name><surname>Wong</surname><given-names>M.M.</given-names></name><name><surname>Chan</surname><given-names>K.H.</given-names></name><name><surname>Chan</surname><given-names>K.S.</given-names></name><name><surname>Kao</surname><given-names>R.Y.</given-names></name><name><surname>Poon</surname><given-names>L.L.</given-names></name><name><surname>Wong</surname><given-names>C.L.</given-names></name><name><surname>Guan</surname><given-names>Y.</given-names></name></person-group><article-title>Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings</article-title><source>Thorax</source><volume>59</volume><year>2004</year><fpage>252</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">14985565</pub-id></element-citation></ref><ref id="bib0430"><label>86</label><element-citation publication-type="journal" id="sbref0430"><person-group person-group-type="author"><name><surname>Falzarano</surname><given-names>D.</given-names></name><name><surname>de Wit</surname><given-names>E.</given-names></name><name><surname>Martellaro</surname><given-names>C.</given-names></name><name><surname>Callison</surname><given-names>J.</given-names></name><name><surname>Munster</surname><given-names>V.J.</given-names></name><name><surname>Feldmann</surname><given-names>H.</given-names></name></person-group><article-title>Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin</article-title><source>Sci Rep</source><volume>3</volume><year>2013</year><fpage>1686</fpage><pub-id pub-id-type="pmid">23594967</pub-id></element-citation></ref></ref-list><ack id="ack0005"><title>Acknowledgements</title><p>We thank Dr. Karen Kirby for help with the figures. This work was supported, in whole or in part, by <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source> grants AI076119, AI099284, AI100890, AI112417, and GM103368 (SGS). We also acknowledge support from Ministry of Knowledge and Economy, Bilateral International Collaborative R&#x00026;D Program, Republic of Korea.</p></ack></back></article>